<i>MET</i> Amplification Identifies a Small and Aggressive Subgroup of Esophagogastric Adenocarcinoma With Evidence of Responsiveness to Crizotinib
Jochen K. Lennerz(Addgene), A. John Iafrate(Massachusetts General Hospital), Daniel A. Haber(Howard Hughes Medical Institute), Benjamin Solomon(Peter MacCallum Cancer Centre), Kristin Bergethon(Massachusetts General Hospital), Yung‐Jue Bang(Seoul National University), Keith D. Wilner(Pfizer (United States)), James G. Christensen, Jeffrey W. Clark(Massachusetts General Hospital), Stephen B. Fox(Peter MacCallum Cancer Centre), Michael Michael(Ospedale San Donato), Eunice L. Kwak(Harvard University), Ravi Salgia(City Of Hope National Medical Center), A. B. Ackerman(Corner House), Gregory Y. Lauwers(Moffitt Cancer Center)
Cited by 433
Related Papers
Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2010|4.5k
<i>MET</i> Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
|Science|2007|4.5k
Isolation of rare circulating tumour cells in cancer patients by microchip technology
|Nature|2007|3.5k
Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer
|New England Journal of Medicine|2013|3.4k